Telix (TLX) Gets FDA Fast Track for BiPASS Imaging

Telix was granted FDA Fast Track designation for its BiPASS pre—biopsy prostate cancer imaging.Material DetailsContext by AI AnalystThis is an early regulatory acceleration step that could speed development of Telix’s imaging candidate. A larger catalyst would be positive clinical data, regulatory…